Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413

Br J Cancer. 1997;76(1):90-2. doi: 10.1038/bjc.1997.341.

Abstract

Thirty-three patients with lung cancer receiving 80 mg m(-2) cisplatin were treated with high-dose dexamethasone (32 mg m(-2) on days 1-3, 16 mg m(-2) on day 4 and 8 mg m(-2) on day 5) combined with granisetron on day 1 and metoclopramide on days 2-5. Twenty-eight (85%) patients had no nausea or vomiting on day 1, and 16 (48%) achieved total control on days 1-5 with acceptable toxicity. High-dose dexamethasone for cisplatin-induced delayed emesis should be further evaluated in a phase III trial.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiemetics / therapeutic use*
  • Cisplatin / adverse effects*
  • Dexamethasone / adverse effects
  • Dexamethasone / therapeutic use*
  • Female
  • Granisetron / therapeutic use
  • Humans
  • Lung Neoplasms / drug therapy*
  • Male
  • Metoclopramide / therapeutic use
  • Middle Aged
  • Vomiting / chemically induced
  • Vomiting / prevention & control*

Substances

  • Antiemetics
  • Dexamethasone
  • Metoclopramide
  • Cisplatin
  • Granisetron